
|Articles|September 7, 2007
BAC free glaucoma therapy welcomed in Japan
The Ministry of Health, Labour and Welfare in Japan has approved Alcon's treatment for glaucoma and ocular hypertension, TRAVATANZ 0.004%.
Advertisement
The Ministry of Health, Labour and Welfare in Japan has approved Alcon's treatment for glaucoma and ocular hypertension, TRAVATANZ 0.004%.
TRAVATANZ is the first prostaglandin analogue that does not contain benzalkonium chloride (BAC), a preservative that is commonly used in topical ocular medications. Recent research has suggested that BAC could negatively affect the ocular surface. To this end, Alcon developed TRAVATANZ as a BAC free version of it glaucoma therapy, TRAVATAN.
TRAVATANZ was approved as TRAVATAN Z in the US in 2006.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Why ST-100 is expanding from dry eye into corneal wound healing
2
Q&A: GLP-1 RAs and NAION, the case for a baseline exam
3
Eichenbaum Acorns: Building the private academic model with Jeffrey S. Heier, MD
4
FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room
5











